Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Portfolio Pulse from Vandana Singh
Eli Lilly (LLY) plans to introduce its obesity drug, tirzepatide, in India next year, competing with Novo Nordisk's (NVO) Wegovy. Bristol Myers Squibb (BMY) is expanding its R&D in India, with a $100-million facility in Hyderabad to become its largest unit outside the U.S. by 2025. The companies aim to tap into the Indian market, emphasizing the need for better patent protection and policy reforms in India.
February 28, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb is expanding its R&D footprint in India with a $100-million facility in Hyderabad, aiming to become the company's largest unit outside the U.S. by 2025.
The expansion of Bristol Myers Squibb's R&D capabilities in India is a significant investment in innovation and development, likely to enhance its global operations and product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Eli Lilly plans to introduce its obesity drug, tirzepatide, in India, aiming to tap into the growing market for diabetes and weight loss treatments.
Entering the Indian market with tirzepatide could significantly boost Eli Lilly's global sales, given India's large population and increasing incidence of obesity and diabetes.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Novo Nordisk plans to introduce its weight-loss drug, Wegovy, in India by 2026, competing directly with Eli Lilly's tirzepatide.
The introduction of Wegovy in India represents a strategic move to capture market share in the obesity and diabetes treatment sector, competing with Eli Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70